ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)

NCT05601752 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

66

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer

Interventions

GENETIC: Autologous genetically modified ADP-A2M4CD8 cells
COMBINATION_PRODUCT: Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab

Sponsor

USWM CT, LLC

Collaborators

[object Object]